Parasite study suggests need for rethink on malaria treatments
Fresh discoveries about how the malaria parasite responds to drugs could help inform strategies for treating infection
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Pricing it right
The long pending decision on drug price policy finally seems to be coming to a conclusion, thanks to a firm push from the Supreme…
’Unless an ethics committee is accredited, it should not function’
In a high level meeting held at the Apollo Group of Hospitals, Delhi, experts from various institutions, deliberated on the need…
Reversing the trend
Despite its role in maintaining health, the antibiotics market has seen considerable downturn over the last few decades. Sachin…
ABLE, WBBA sign MOU to support discoveries for better healthcare solutions
The Association of Biotechnology Led Enterprises (ABLE), and US-based Washington Biotechnology & Biomedical Association (WBBA)…
GoI to introduce innovative R&D focused pharma cluster scheme
Targeted to attract Indian R&D professionals to return & start up in India
Ranbaxy launches authorised generic of Evoxac in US healthcare market
Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren’s syndrome
WHO prequalifies Ciplas ‘MEFLIAM Plus’ for treatment of malaria
MEFLIAM Plus, an Artesunate-Mefloquine fixed-dose combination to be rolled out throughout Asia
ABLE and WBBA sign MOU to support breakthrough discoveries for better healthcare solutions
Join hands for co-operation and investment in the field of biotechnology
Takeda and Advinus initiate multi-year drug discovery collaboration
To focus on novel targets for major therapeutic areas, including inflammation, CNS, and metabolic diseases